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ABSTRACT 
BACKGROUND AND OBJECTIVES 
A positive association between platelet indices and the development of 
acute coronary syndromes has been reported. The aims of the study were to 
compare the platelet indices in patients with ACS and those with non cardiac 
chest pain and to study other risk factors which took part in the development of 
ACS. 
METHODS 
Ethical committee clearance was obtained .After taking consent  eighty 
five patients with ACS were taken  and 85 patients with non cardiac chest pain 
were selected for the study. All subjects were in the group of 35-70 years. They 
were further divided into groups based on age, gender , BMI , history of 
diabetes, total cholesterol, family history, history of hypertension .These 
groups were studied for influences on ACS. The association of platelet indices 
such as mean platelet volume (MPV), plateletcrit (PCT) ,platelet distribution 
width(PDW)  with ACS were studied. The data was analysed by SPSS version 
20.0 
RESULTS 
The mean MPV of study participants  with ACS were 12.468. The mean 
MPV of study non ACS patients  were  10.636 .The mean PDW of study 
participants  with ACS were 19.134. The mean PDW of study participants  
without ACS were 13.611. The mean PCT of study participants were in ACS 
patients was 3.1. The mean PCT of study participants  who had no acute 
coronary event were 2.19 . 
CONCLUSIONS  
Platelet indices had significant variation in patients with ACS. Patients 
of male gender were also presented frequently to the casualty with chest pain 
and were diagnosed to have ACS than females. Diabetes also significantly 
contributed to development of ACS. Higher total cholesterol was aculprit in the 
development of acute cardiac events. A patients BMI was also significant risk 
factor. Therefore platelet indices can be used as a economic marker of an acute 
coronary event . 
Keywords : platelet indices, ACS  
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INTRODUCTION 
Acute coronary syndrome (ACS) is a spectrum of conditions due to 
decreased blood flow in the coronary arteries such that part of the cardiac 
muscle is not able to function properly or dies and that is a result of platelet 
rich coronary thrombus formation.1 
Plateletsfor long time have been implicated in the pathogenesis of 
cardiovascular diseases including atherosclerosis and its complications such as 
acute myocardial infarction, unstable angina and sudden cardiac death. Platelet 
hyperactivity and local platelet activation have been found to play a role in 
acute coronary events.2 
Activated platelets are larger in size,  and  they  can be measured by 
mean platelet volume (MPV)1 .When platelets are  larger, they become 
metabolically and enzymatically active. Platelet indices corresponds  to  
functional status of platelets and is an emerging risk factor for 
atherothrombosis.2 
Increased platelet activation may also represent the net  patho - 
physiological effects of a number of cardiovascular risk factors, such as 
smoking and dyslipidaemia, thus representing a broad marker of CVD risk. 
Platelet activation leads to a more spherical  shape  with increased platelet 
swelling and thereby leading to an increase in platelet mass and volume.3 
Free arachidonic acid is also formed due to platelet activation, which 
may  be converted into prostaglandins, also  known  as  thromboxane A2. It  
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isone of the most potent vasoconstrictor and platelet-aggregating substances, or 
into leukotrienes, which amplifies the acute inflammatory response. 
Platelet function and size correlate because larger platelets, produced 
from activated megakaryocyte in the bone marrow, are likely to be more 
reactive than normal platelets because large platelets contain more of secretary 
granules and mitochondria and are known to be more active thanthe  smaller 
platelets (normal).3 
Large platelets are metabolically and enzymatically more active than 
smallerones and secrete and express more mediators such as adhesive proteins 
(fibrinogen, thrombospondin, and fibronectin), growth factors (plateletderived 
growth factor, transforming growth factor, and basic FGF), and chemotactic 
and mitogenic factors (platelet factor 4, coagulation factors [factor V and factor 
XI], and cytokinelike factors [interleukin1 and CD40ligand].5 
Larger platelets as measured by their volumes (MPV) may be useful 
markers in patients with ACS.Higher MPV may become useful marker for 
early detection of ACS along with other biomarkers. 
Patients with increased MPV could be easily identified during routine 
haematological analysis. It could play an important role in early detection of 
acute coronary syndrome (ACS) and beneficial for preventive treatment. It 
could be used as a screening test to differentiate the origin of chest pain along 
with other cardiac biomarkers. 
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A few reports published have revealed a larger MPV in Indian patients 
with ACS compared with healthy controls or patients with stable coronary 
artery disease.4 
Unlike all other markers of platelet activation and reactivity, it is 
automatically calculated by most equipment for performing blood cell count.5 
Thus, to determine the platelet sizethrough MPV is a simple, extremely 
inexpensive, and readily available measure in hospital and outpatient settings.5 
The commonest finding of ACS is ST elevation MI. Analysis of PVI 
indicated MPV & PDW as an important risk factor for developing a myocardial 
infarction. This was along with the elevated cardiac enzymes levels.2 
MPV had higher sensitivity and specificity when compared  to platelet 
count. MPV maybe  used as predictor for early detection of ACS and risk 
stratification when other cardiac biomarkers are negative.1 
Platelets with higher PCT and PDW were at higher risk of ACS. These 
patients can easily be identified during routine hematological examination and 
the patients could possibly benefit from preventive treatment.1 
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AIMS AND OBJECTIVES 
• To compare the platelet indices in patients with ACS and those with non 
cardiac chest pain. 
• To correlate the platelet indices and patients diagnosed with Acute 
Coronary Syndromes. 
• To study factors associated with variation of platelet indices in ACS and 
non ACS patients. 
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SCIENTIFIC JUSTIFICATION OF THE STUDY: 
The WHO has given attention to the fact that coronary artery disease is a 
modern epidemic more in geriatric population, that is, people above 60 years of 
age. An increase in coronary artery disease has been bought into the light and 
now it is the most common cause of death. 
Previous data suggests that only 1/3rd of chest pain cases require critical 
care and hospitalization but in the absence of segregation of these cases in the 
beginning, physicians over admit such patients and it burns out the precious 
resources  in the public  setup. Further it may hamper the quality of care for 
those who actually require it.9 
Platelet indices is a simple and economic laboratory measurement (less 
costly and can be done  when a complete blood count is already requested), we  
suggest that it might be useful as an assisting rule-out test in conjunction with 
other conventional biochemical cardiac markers in the early prediction of the 
risk of ACS in patients admitted to the emergency department. 
Hence, in this protocol we are doing a hospital based study to find out 
the changes that occur in platelet indices to provide early diagnosis of an acute 
coronary event. Moreover a study in this topic has not yet been done in the 
Kanyakumari district of   Tamilnadu, India. 
Review of Literature 
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REVIEW OF LITERATURE 
WORLDWIDE BURDEN OF ACUTE CORONARY SYNDROME 
Ischemic heart disease (IHD) is the single major cause of mortality and 
loss of disability adjusted life years (DALYs) in  the whole world, accounting 
for roughly seven million deaths and129 million DALYs annually.When high-
income countries (HICs) continue to deal with significant IHD mortality, 
almost two-thirds of all IHD DALYs and over half of deaths occur in LMICs. 
Many of these countries have undergone exponential economic growth and 
lifestyle changes over the past several years that have increased theburden of 
IHD risk factors and rates of mortality.47 
 
 
 
 
 
 
 
 
                  FIG.1:  Worldwide Burden of Acute Coronary Syndrome47 
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According to the Global Burden of Disease study age-standardized 
estimates (2010), almosta quarter (24.8%) of the mortality in India can be 
attributed  to CVD. The age standardized CVD death rate of 272 per 100 000 
population in India is more than the global average of 235 per 100 000 
population. 
Eventhough CVD risk factors are widely prevalent in India, there are 
significant variations between and within different regions. Diabetes mellitus is 
found to be more prevalent in the southern states of India, whereas 
hypertension seems to be higher in the northeastern states. This heterogeneity 
can be related  to diversity in culture (leading to differences in dietary 
practices, tobacco use, and physical  activity ) and variations in economic 
development between and within different regions  of India. Spectrum of ACS 
in North Eastern India and has noticed few key differences from national 
registry,  which has greater percentage of STEMI patients, a greater delay in 
seeking critical care, greater 30-day mortality, and lesser percentage of patients 
receiving reperfusion therapy.16 
Facing the epidemic requires the development of plans such as the 
formulation and effective implementation of evidence based policy, 
reinforcement of  the medical systems, and more stress laid  on prevention, 
early detection, and treatment with the help of both conventional and 
innovative techniques. Many ongoing community-based studies are verifying 
Review of Literature 
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these strategies and within different states in India, it is important to understand 
the social determinants.21 
Patients with ischemic heart disease are divided into two large groups: 
patientswith chronic coronary artery disease (CAD) who most  commonly  
present  with  stable  angina  and patients with acute coronary syndromes 
(ACSs) . These consists of patients with acute myocardial infarction with ST-
segment elevation  (STEMI)  on  their  presenting  electrocardiogram  and 
those with non ST segment elevation acute coronary syndrome (NSTE-ACS).  
The second group include patients with non-ST -segment elevation 
myocardial infarction (NSTEMI), whoby definitionhave finding  of myocyte 
necrosis, and those with unstable angina (UA), who do not. The  incidence 
relatively of NSTEMI compared to STEMI appears to be on the increase.23 
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CLINICAL PRESENTATION 
Diagnosis 
The diagnosis of NSTE-ACS depends largely on the clinical 
presentation. Usually, chest discomfort is severe and has at least one of three  
clinical  features:  
1. It occurs at rest (or with minimal exertion lasting for more than 10 
minutes ) 
2. It is of  recent onset (i.e. within the prior 2weeks); and/or  
3. It occurs with a crescendo pattern (i.e. more severe, prolonged, or 
frequent than previous episodes) .  
The diagnosis of ACS is confirmed if a patient with these clinical 
features develops evidence of myocardial necrosis， which is  reflected as 
abnormally elevated levels of biomarkers of cardiac necrosis.23  
THE PATHOPHYSIOLOGY OF ACUTE CORONARY SYNDROMES 
The importance of thrombosis as the trigger for acute myocardial 
ischaemia is well known, it is  of great use  to  know  something  about  the 
structure of plaques before thrombotic events occur and why there is  a sudden 
change from a stable state (where there is no thrombus) to an unstable state 
(thrombus).24 
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Atherosclerosis 
It is described  as a “response to injury”   which was  first  suggested  by  
Russell  Ross  in  1973.  There are four steps in his model:  
1) Endothelial   damage,   
2) Migration  of  LDL particles through the endothelial layer  into  the  
intima  where  they  are  modified,  
3) Inflammation mediated     responses,  
4) Formation  of  a fibrous  cap.     
Theendothelium  is prone for damage by  various factors  such  as  
hypertension,  type 2 diabetes mellitus,  tobacco,  infections, or  even oxidative 
and shear stress.24 
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If the patient has a large patch of myocardial ischemia or a large 
NSTEMI， the physical findings will be  diaphoresis; pale, cool skin; sinus 
tachycardia; a third and/or fourth heart sound; basilar rales; and occassionally, 
hypotension.23 
ELECTROCARDIOGRAM  IN  CAD 
• A 12 lead resting ECG (± RV3, RV4 for right ventricular MI) should 
be taken immediately in patients with ongoing chest pain as early  as 
possible within 10 minutesof presentation. 
• A normal ECG which may not be consistent even in the  presence of 
severe CAD, and ECG should be taken or repeated ifstrong suspicion in 
every 4-6 hours or earlier. 
ECG abnormality includes: 
 Resting ST segment changes (depression ≥ 0.5 mm horizontal or 
downsloping in NSTEMI, convex elevation > 1mm in ≥2 consecutive 
leads in STEMI, pseudonormalization of ST segment or dynamic 
changes). 
 New pathological Q-waves (>0.4 seconds) is usually diagnostic of MI, 
but may occurwith prolonged ischemia. 
 T wave-inversion (≥ 2 mm symmetrical) or a peaked upright T waves 
may be the firstECG changes of Myocardial Ischemia. 
 New onset LBBB 
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LABORATORY STUDIES26 
• Blood samples should be sent for cardiac enzymes (biomarkers 
Troponin I or T and CKMB) for confirmation  of ACS; complete blood 
haemogram, blood urea, creatinine, electrolytes, FBS –formonitoring 
and Fasting lipid profile- for secondary prevention. Cardiac specific 
troponinis the preferred biomarker for diagnosis of STEMI. The 
advantage of  Troponin I is that it does not alter with renal failure.A 
portable chest radiograph is useful to exclude other  non cardiac causes 
of acute chest pain but itshould not delay the treatment. 
• Imaging:2D echocardiography: Abnormalities of wall motion are 
almost alwayspresent in STEMI. Estimation of left ventricular (LV) 
function is usefulin the long run . It identifies the presence of right 
ventricular (RV)infarction, ventricular aneurysm, pericardial effusion, 
and LV appendage thrombus. 
• Doppler echocardiography: it is useful in detection and quantification  
of aventricular septal defect and mitral regurgitation.26 
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Management of   patients diagnosed with  NSTEMI 
Those patients with  probability of  NSTE-ACS and  who are stable 
should be admitted on an inpatient basis for bedrest with continuous  
monitoring of rhythmand careful observation for  any recurrence of ischaemia  
. High risk patients, especially those with continuing discomfort and/or 
haemodynamic instability, should beimmediately shifted to a coronary care unit 
(CCU)and observed for at least 24-48 hours.Fibrinolytic (thrombolytic) therapy 
which uses streptokinase, urokinase, tenecteplase orany other agent should not 
be instigated inpatients with UA and NSTEMI. Theseagents may definitely  
prove harmful. GlycoproteinIIb/IIIa agents like abciximab, 
tirofibanandeptifibatide are seen to be useful inpatients undergoing 
percutaneous coronary interventions (PCI). 
1)Anti- ischemic and analgesic medications 
Oxygen is very useful for initial stabilizationspecifically in those with 
hypoxemia. 
Topical, oral or intravenous nitrates are very useful for pain relief. 
Intravenous nitroglycerin (NTG) is helpful in those who are resistant or 
unresponsive  to sublingualNTG, in those with hypertension and  heart failure. 
This drug  should be used cautiously if systolic blood pressure is below 100 
mm of Hg. 
Review of Literature 
 
 
20 
 
The nonsteroidal anti-inflammatory drugs (NSAIDs) andCOX-2 
inhibitors is not recommended for pain relief. There is increased risk of 
cardiovascular events. The use of morphine also not specified  in UA/NSTEMI. 
 Beta blockers are found to be  useful for pain relief. The administration  
of intravenous beta blockers should be withheld particularly in unstable 
patients. Calcium channel blockers are of use in vasospastic angina and in 
patients who have contraindications to betablockade. Some of the other 
antianginal drugs like ivabradine, trimetazidine, ranolazine and nicorandil are 
found to Have very limited role. 
2)Antiplatelet agents used in NSTEMI 
Admintration of Aspirin to all patients unless contraindicated and as 
mentioned earlier, first  dose of chewed non-enteric aspirin varying  from 162 
to 325 mg is given.  Subsequent dose of aspirin can be 75 to 100mg daily  
which is on a long term basis. The chances of gastro intestinal bleeding appears 
to increase with higher doses. 
Clopidogrel is  given in all  the patients with animmediate dose of 300 
mg followed by 75 mg on a  daily basis. In patients who are being planned  for 
a PCI, a loading dose of 600 mg is advised to achieve more rapid inhibition of 
platelet function. Clopidogrel should be maintained for at least 12 months 
unless there is an increased risk of bleeding. 
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3) Current recommendations for Anticoagulant therapy 
Anticoagulation therapyis strictly recommended for all patients in 
additional to antiplatelet agents. Many number of agentsare available which  
include unfractionated heparin (UFH),low molecular weight heparin (LMWH), 
fondaparinux andbivalirudin. The choice of drug  mainlydepends on therisk of 
ischemic and bleeding episodes  and the choice of the initialmanagement 
strategy (e.g. urgently invasive, early invasive or even when conservative). 
Enoxaparin (1mg/kg bw twice daily) is the  preferredanticoagulant and 
is a good option in patients who are  treatedconservatively or even  by invasive 
strategy. Enoxaparin is usually stopped within 24 h after an invasive strategy 
and it should be administered up to hospital discharge (usually 3 to 5 
days)during  conservative strategy. 
Fondaparinux is used based on  favourable efficacy/ safety profile and 
the recommended  daily dosage of  2.5 mg . This agent has the least bleeding 
complications. An additional UFH in standard dose of 50-100 U/kg bolus 
ismandatory  during PCI due to slightly high incidence of catheterthrombosis. 
Statins are given  for all NSTE ACS patients, irrespective of cholesterol 
levels,  and is initiated early upon  admission,with the  main aim of achieving 
LDL C levels <70 mg/dL. Atorvastatin is usual agent which is preffered, at a 
dose of 80mg per day. ACE inhibitors are prescribed in patients with reduced 
LV systolicfunction. Whereas ARB’s areonly  indicated in those patients who 
are intolerant to ACE in hibitiors. 
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4)Coronary intervention  
Revascularization for NSTE ACS is done to  give relief from  angina, 
ongoing myocardial ischemia and to prevent the  progression to MI or death. 
The decision for revascularization as thepreferred approach, PCI or CABGS  
totally depends on the extent andseverity of the lesions, the patient’s  general 
condition and co-morbidities . 
Approach in the long run  
Patients diagnosed with  NSTE ACS after the initial phase usually  carry 
a highrisk of recurrence of ischemic events. Therefore, anactive 
secondaryprevention is an essential componentof long term management. 
Life style modification, weight loss, strict blood pressure control and 
monitoring, control and management of diabetes, lipid profile  intervention, 
antiplatelet therapy ,beta blockers, ACE inhibitors (or ARB) remain to be 
watched out for. 
Management of  patients diagnosed with STEMI 
The initial treatment that should be given is 325 mg of(preferably) non 
enteric-coated aspirin which can  be chewed. Irrespectively all patients should 
receive aspirin. Clopidogrel is  administered as a loading dose of 300 to 600 
mg to all  the patients. Patients  who are going to undergo primary PCI should 
receive a 600 mg loading dose. 
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All patients should be given  medications to relieve pain. It may include 
opioid analgesics (morphine sulfate intravenously). Sublingual or intravenous 
nitrates can be administered if systolic blood pressure is ≥120 mm Hg. 
But if systolic BP is ≥100 mm Hg but less than 120 mm Hg,then  
nitrates should be administered cautiously. Non-steroidal anti-inflammatory 
drugs. (NSAIDs, other than aspirin) is  not be given for analgesia. 
Reperfusion therapy is said to be the cornerstone of STEMI 
management and should be initiated in all the patients presenting within 
12hours of onset of symptoms. The most effective reperfusion therapy 
available is timely primary PCI, but it may not be as  effective in the Indian 
context when compared to the western population , given to  the relative 
deficiency  of PCI-capable centers. Moreover, since most of these centers for 
PCI are located in the urban areas, the distances involved in transporting 
patients from rural are as  to urban becomes time consuming. 
Fibrinolytictherapy therefore remains the most effective practicable reperfusion 
treatment strategy for India. 
Fibrinolytic therapy in STEMI patients  
As a norm , streptokinase is  the most frequently used fibrinolytic agent 
in India. Recently, there has been  some favorable evidence for the use of 
Tenecteplase in Indian settings. Tenecteplase has been found to be 
fibrinspecific,can be given as a bolus dose, and has a lower incidenceof allergic 
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reactions. Tenecteplaseis usually administered at a dose of 0.5 mg/kg body 
weight. 
Immediate Transportation of Patients to Centers equipped with CCUs 
and/or PCI  
The delay to access the  hospital can be reduced by institutionof systems 
to  be initiated as pre-hospital protocol and fibrinolysis.Pre-hospital fibrinolytic 
therapy has clearly proved  to improveoutcomes as compared to  primary 
PCI.But recently  studies in Europe and North America have shown that 
transport of patients to PCI-capable centers may be a betterstrategy than 
immediate fibrinolytic therapy. But such may  not be suitable for most parts of 
India becauseof the long  distances that are  involved and the difficulty  
oftransport. But still , it may be possible for small  urban and rural to develop 
systems for the provision ofefficient services for transporting such   patients to 
designated PCI capable centers. 
After the administration of fibrinolytic therapy some  situations may 
necessitate transfer of such  patients to such  centers those indications are: 
1. Those patients who are in cardiogenic shock or those who are at high 
risk of developing the same. 
2. Those patients with failed fibrinolytic therapy 
3. High-risk patients. 
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Antiplatelet therapy in STEMI patients  
Aspirin and clopidogrel should be given per oral as initially discussed. 
That is maintenance dose aspirin (75-100 mg) and clopidogrel (75 mg) should 
be given. 
As per the latest ACC/AHA guidelines, GlycoproteinIIb/IIIa antagonists 
can be selectively used in patientsundergoing primary PCI I when in the setting 
of dual antiplatelet therapy with UFH is used  as the anticoagulant inthe 
catheterization laboratory, during  the procedurewhere large thrombus burden 
is present  or patient has received an  inadequate thienopyridine loading. 
There is no role of administration of these agents to bridge the time 
delay before primary PCI(facilitated PCI). Abciximab, eptifibatide and 
tirofiban appear to be as effective and can  be used depending upon the treating 
physician’s  preferences and availability. 
Antithrombotic Therapy 
After the treatment with both fibrin-specific and non fibrin specific 
fibrinolytic agents, there is strong indication for the usage  of antithrombotic 
agents for reducing reinfarction or recurrent schemia. Recent studies 
havesuggested  that low molecular weight heparins (LMWH) can  be better 
than unfractionated heparin(UFH)  and for this purpose,the LMWHs  
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Enoxaparin or reviparin 
Can be administered even  for up to 8 days post-MI. Fondaparinux has 
been shown to decrease the occurrence of mortality  or reinfarction while  side 
to side reducing the risk of major bleeding, and may therefore be considered in 
patients who are undergoing treatment with streptokinase.There  seems to be no 
role forbivalirudin among patients who are on  fibrinolytic therapy. Patients are 
to undergo  primary PCI should receive peri procedural UFH26 or bivalirudin. 
Fondaparinux (without added UFH) is found to increase the risk of catheter 
thrombosis. 
Beta Adrenergic Antagonists 
Oral beta-blockers is usually  administered by the first  24 hoursto 
patients who are not in  heart failure, or a low output state, or not at  an  
increased risk of having  cardiogenic shock, or those who donot have other 
contraindications to beta-blocker therapy.In case  ACEinhibitors and ARBs’, 
care should be taken to avoid hypotension. 
ACE inhibitors are found to improve survival in those patients who have 
reduced left ventricular ejection fraction (LVEF ≤40%) and in those who are in 
heart failure following acute coronary event . Benefits areproportionately lower 
among low risk patients. ACE inhibitors are to  be started in the first 24 hours 
after STEMI unless contraindicated . ARBs can  be used in patients who do not 
tolerate ACE inhibitors. 
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Use of intravenous or oral nitratesis shown not to  improveoutcomes in 
patients with STEMI. Nitrates can  be used for pain relief. There has been no 
role for the routine use of calcium antagonists,intravenous magnesium,  and 
antiarrhythmic drugs  or glucoseinsulin-potassium infusions, and these 
therapies  may be associated with adverseoutcomes in some cases. High doses 
of  statins should be started as early as allowed during hospital stay as part of se 
prevention measures. The dose of statin  used in Indian patients is not studied , 
but lowering LDL levels to ≤80mg/dL may serve as  a useful target. 
Many  studies have suggested that routine angiographyand PCI of the 
infarct related artery may decrease  the  chances of reocclusion or reinfarction. 
Some other recent data  clearly suggests that Pharmaco-invasive therapy has an 
important place in  the improvement of the prognosis of patientsafter 
thrombolysis. Unlike facilitated PCI after which patients are immediately taken 
up for PCI after thrombolysis.  
It has been increasingly been seen that patients after a 
successfulthrombolysis are to be transferred to facilities with   cardiac cath 
laboratory for coronary angiography and, if needed, a PCIwith stent 
deployment. 
However, because of the intensive  resources used up  for  thisstrategy 
and in  the absence of an effect on survival in many  studies most guidelines 
still uphold a more conservative dimension which  consists  of 
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Platelet adhesion35 
In response to endothelial damage the platelets, which usually circulate 
in an isolated fashion, instead adhere  to the subendothelial matrix. This causes 
interaction between platelet membrane glycoproteins and adhesive protein from 
the endothelium, collagen and the Von Willebrand factor (VWF). 
 Under reduced flow conditions, this interaction is conducted by  GPIa-
IIa platelet glycoprotein; under turbulent  flow conditions, the GPIb-IX-V 
complex participates. 
GPVI (62 kDa) belongs to the class of  immunoglobulin superfamily 
and, along with GPIa-IIa, acts as a collagen receptor. On the surface of the 
platelet, it forms a complex with the receptor Fcγ, activating the 
phosphorylation of a cytoplasmatic segment of the receptor and thereby 
causing  platelet activation. 
The GPIb -IX complex (CD42b, CD42a, CD42d) functions as a receptor 
for FVW, taking part in the platelet adhesion process. Resting platelets express 
~25,000 copies of this glycoprotein complex . 
Platelet aggregation.35 
When  the platelets have adhered, they assume a spherical  form with 
extensions that exhibit the GPIIb-IIIa complex, forming dimers of the 
glycoprotein to attach the fibrinogen or FVW, according to the flow, and to 
release the content of their granules. This activates and adds more platelets 
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The GPIIb-IIIa complex (integrin αIIbs3, CD41-CD61) is a 228-kDa 
heterodimer whose structure consists of an extracellular domain as a 
transmembrane and a small cytoplasmatic domain. Every single platelet 
displays ~40,000-50,000 copies of this glycoprotein complex. 
As well as binding fibrinogen and FVW, the GPIIb-IIIa complex it can 
also bind to fibronectin and vitronectin, thus taking part in the adhesion and 
aggregation of the platelet mechanism. 
Platelet secretion35 
There are two types of granules  which are functionally the most 
important in platelets: α granules and dense granules. Αlpha granules store 
large amounts of proteins, among them fibrinogen, FVW, platelet factor 4 
(PF4), GPIIb-IIIa, FV, FVIII, FXI, platelet-derived growth factor (PDGF) and 
epidermal growth factor (EGF), which takes part in platelet aggregation. 
Whereas  dense granules are rich in calcium, phosphorus, ADP and ATP; the 
release of dense granule content has a special place  in the amplification of the 
platelet response. 
Pro-coagulant activity35 
 Lipid deposition  in the platelet membrane is of functional importance. 
Two enzymes, a translocase specific to aminophospholipids and a flopase, 
maintain the asymmetric state of phospholipids in the membrane. 
During the activation of platelets, there will be a redistribution of 
anionic phospholipids, mainly phosphatidylserine (PS), which occurs from 
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inside to outside by the action of the enzyme scramblase , which is activated by 
the increase in cytosolic calcium of platelets and creates a surface with a 
anionic electric charge .  
This favours the formation of coagulation complexes and, consequently, 
the formation of fibrin and the consolidation of the thrombus. 
PLATELET DISORDERS 
Disorder of platelet adhesion : 
1)Ehlers-Danlos Syndrome 
It is one of the inherited disorders of collagen biosynthesis, such as the 
Ehlers-Danlos syndrome which is  characterized  by extremely fragile skin and 
easy bruisability. Such patients may sustain severe and  extensive ecchymoses 
even from minimal trauma. While looking into  Ehlers-Danlos syndrome type 
IV, there is a pronounced chance  of  easy bruising which may lead  to sudden 
death from spontaneous hemorrhage as a consequence  of arterial rupture. 
Abnormal bleeding has been  thought to be the as a  result  defective 
connective tissues. For example, Ehlers-Danlos syndrome type IV is 
characterized by a deficiency of type III collagen in the skin and vessel wall. 
Poor connective tissue linkage  has more chances  for vessel wall 
rupture, very poor vessel wall retraction after disruption and seepage  of the 
hematoma along  very fragile tissue planes. Intrinsic platelet function is usually 
seen to be  normal in this syndrome, but defective platelet adhesion due to the 
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disrupted defective vessel wall impairs platelet plug formation and leads to a 
bleeding disorder simulating qualitative platelet defects. The diagnosis is 
suspected on clinical examination  along with normal findings on in vitro tests 
of hemostasis. 
SCURVY 
Scurvy, is an acquired platelet  disorder which is  now rarely seen, may  
usually be associated with a significant bleeding diasthesis, which is  the result 
of a connective tissue disorder  caused by vitamin C deficiency. The deficiency 
of vitamin C  impairs the synthesis of hydroxyproline, an important building 
material  of normal collagen. 
Theresultant defective collagen weakens the connective tissue, 
producing bleeding manifestations such as gum bleeding, and subcutaneous 
and intramuscular hemorrhages. It is characteristic of  perifollicular petechiae. 
The bleeding time can be slightly increased and invitro platelet function is 
normal. Scurvy responds within few weeks following oraladministration of 
vitamin C. 
AMYLOIDOSIS 
It is a disorder  in which purpura may be acquired from the diffuse 
vascular and mucosal infiltration which  occurs in systemic amyloidosis. 
Periorbital purpura is typical. 
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The chance of hemorrhage is higher  after minor surgical procedures 
such as skin, gum or liver biopsy. When amyloidosis occurs in combination 
with plasma cell myeloma, the hemostatic defects resulting from the latter 
condition may again  further increase the risk  of  bleeding tendency.  
DISORDERS OF PLATELET ADHESION 
Bernard-Soulier Syndrome 
This syndrome is a rare, familialbleeding disorder  which is of moderate 
severity characterizedclinically by mainly bleeding from the nose, 
menorrhagia, and cutaneous and visceral haemorrhages. The platelet count can 
be variable, and on the blood film the platelets is seen to be enlargeddue to   
their flat disc shape. 
The bleeding time is significantlyprolongedthatis, more than 20 minutes. 
Ristocetin-induced platelet aggregation is not seen and can  not be corrected by 
the addition of exogenous, von Willebrand factor. Other factors of platelet 
aggregation is normal . 
The defective hemostasis in this syndromeis secondarydue  to an 
intrinsic defect of platelet adhesionto subendothelium. The membrane 
glycoprotein of platelets from these patients shows reduced number of 
membrane glycoproteins designated GPIb and GPIs (glycocalicin).  
There supportive evidence for the hypothesis that the absenceof these 
membrane glycoproteins is responsiblefor the observed functional defect. It has 
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been studied  that this glycoprotein I complexusually  acts as the platelet 
receptor through which the von Willebrand factor is a mediator  not only the 
platelet subendothelium interaction but also in the vitro ristocetin-induced 
platelet aggregation . 
Von Willebrand Disease 
It is a common heterogeneous group of congenital bleeding disorders, in 
which an increased bleeding time and defective hemostasis are the result 
offactor VIII/von Willebrand factor (FVIII/VWF). 
The disease’s classic form  isinherited as an autosomal dominant trait 
and it  is characterized by a mild to moderatebleeding tendency that frequently 
involves bleeding from the nose (epistaxis), severe gum bleeding, menorrhagia 
or postoperativehaemorrhage . Gastrointestinal, muscle andjoint bleeding are 
uncommon .The bleeding time is prolonged. Biochemically, it can be divided 
into two main variants and is defined on the basis oflaboratory findings. In type 
1 there is a simultaneous reduction in factors such as Ag and Co. In type 2, a 
qualitative defect of Factor 8/VWF complex can be shown on 
radiocrossedimmunoelectrophoresis, which shows the absence of the larger 
molecules  of the above said complex. 
An uncommon  but more severe form of von Willebrand disease is 
passed over as an autosomalrecessive trait and it is  similar to hemophilia. 
Muscle, gastrointestinal and haemarthrosis, as well as  bleeding from the 
are the most commonclinical manifestations. The disease is inheritedfrom both 
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the parents, eventhough the heterozygoteparents are most of the time clinically 
normal or have onlya mild bleeding tendency with modest abnormalities of the 
same complex. The template bleeding time in diseased  patients is greatly 
increased . 
Qualitative and quantitative defects of the complex can be seen 
oncrossed immunoelectrophoresis. Studies haverevealed  that the Factor 8:Ag 
level is significantly reduced and a small amount of antigenthat is also present 
is abnormal configuration . 
Uremia 
It causes  an extrinsic platelet defect due to  the progressive rapid  
accumulation of metabolicproducts in the blood. In previously untreated 
patients with uremia the template bleeding time is  prolonged for more than 30 
minutes and, as predicted , reduces to near normal in those  taken up  peritoneal 
dialysis. Hemodialysis seems to be less effectivein this regard. 
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STUDIES RELATED TO ACS AND PLATELET INDICES 
Ridavanet al. did a study in 2010 in Turkey on mean platelet volume and 
its association with acute coronary syndrome. From a population of 214 
patients where69 were with acute MI, 73 were with unstable angina pectoris, 
72 patients with stable angina pectoris and control group of 45 patients who 
had atypical chest pain with no pathological signs in coronary angiography. 
They found out that mean platelet volume was increased in patients Acute 
Coronary Syndrome.6 
Pervin et al .did   a study in Bangladesh in 2011 on 79 patients 
diagnosed with ACS based on clinical history, ECG and increased troponin I 
with 63 subjects as control. They found out that Mean Platelet volume (MPV) 
had higher sensitivity and specificity in contrast to platelet count and can be 
used for early detection of Acute Coronary Syndrome. The sensitivity,   
specificity ,  accuracy, positive and negative  predictive value of platelet counts 
and MPV were 83%, 28.1%, 42.3%, 37.6%, 64% and 90.6%, 49.4%,64.8% 
51.6% ,89.8% respectively.13 
Tomasz et al.did a prospective study  in 2013 in Poland on 538 patients 
who underwent primary PCI in acute MI. Admission samples were measures 
for MPV,PDW and P-LCR and were followed for 26+/-11 months and found 
out that MPV,PDW and P-LCR  measured on admission are strong independent 
prognostic factors in PCI treated acute MI.49 
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Jasmin et al. did a comparative study at SBKS Medical Institute & 
Research Centre,Vadadora in 2014 on 180 patients (60 patients with stable 
angina ,60 with ACS and 60 with non cardiac chest pain). Platelet count and 
volume indices were assayed .In patients with MI ,the mean values of MPV, 
PDW ,platelet count and PC were 11.02fL ,17.85% ,2.61 lac/ cumm and 0.34% 
respectively ,meanwhile normal healthy control the mean values of those 
indices were 7.98Fl, 10.70%, 2.66lac/ cumm and 0.24%respectively.7 
 Randheer et al. did a study in 2014 in SMS Medical College , Rajasthan 
on 215 eligible patients to investigate whether there is an association between 
MPV measurement and cardiac Troponin I (cTn I) in patients with suspected 
diagnosis of ACS. Mean platelet volume (MPV) was found to be higher among 
ACS patients as compared to non ACS, 11.44±1.23 vs 9.91±1.27 fl (p-
value<0.001). The NPV of MPV in the diagnostic workup of chest pain 
suggestive of ACS within 6 hours of presentation were found to be 82.53% .9 
Murazsemiz et al .did a study in Turkey in 2012 in 60 hospitalized 
schizophrenia patients taking atypical antipsychotics to find out what has 
influenced the Mean Platelet Volume levels in patients with schizophrenia 
because cardiovascular diseases are more frequently encountered in in these 
patients compared with general population. MPV levelswere significantly 
higher in patients who were on atypical antipsychotics drugs than in patients 
who were not using any drugs (9.2+/-0.8 vs8.6+/-0.8Fl ,P=0.016)  & also 
higher than in control groups(9.2+/-0.8 vs 8.1+/-0.9Fl,P<0.001).50 
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Nurcan et al. did a study in Turkey in 200  patients to investigate the 
clinical value of MPV in coronary atherosclerosis & it’s possibility of being an 
independent risk factor for acute MI. MPV was found to be elevated in MI 
patients compared with controls (p<0.001) &(SAP<0.05) &patients with  
two(P<0.001) and three vessel (p<0.05) disease. A significant association was 
seen between MI and higher MPV (≥12fL).10 
Awad-Elkareem Abass et al in Sudan did a study 103 patients with 
CAD; and 100 patients with non cardiac chest pain. They found out that Mean 
Platelet Volume, platelet distribution width and platelet large cell ratio were 
significantly higher in ACS compared to controls (P-values<0.05).51 
Abdullah  et al. did a study in Kingdom of Saudia Arabia in 2011 to 
identify to identify diagnostic and prognostic factors for Acute Coronary 
Syndrome in which Mean Platelet Volume  and Platelet Distribution Width 
were also investigated.A retrospective study of 212 patients with ACS and 49 
matched controls. The MPV was significantly larger in MI cases compared to 
controls (8.99±1.5fL vs 8.38±0.5fL,respectively,P<0.009).The MPV was 
significantly higher in MI cases compared to controls (15.88±1.5fL vs 
11.96±1.8fL,respectively,P<0.001).51 
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Ugur et al. did a study in 2012 in Turkey in 441 consequtive  patients 
undergoing coronary angiography by measuring platelet indices .there was no 
statistical difference for platelet count MPV & PDW among the groups 
.correlation analysis showed a positive association between platelet count and 
Gensini scoring (Kendalls tau b ,r=0.312,p=0.037,two tailed)&also age  
(Kendalls tau b,r=0.512,p=0.001,two tailed) in patients with CAD. However 
there was no significant correlation between Gensini scoring &MPV values in 
these patients .8 
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MATERIALS AND METHODS 
Study design: Observational Study. 
Study setting (Exact place where the study is conducted): Department of 
General Medicine and Department of Cardiology, Sree Mookambika Institute 
of Medical Sciences, Kulashekharam, Kanyakumari District during the decided 
study period. 
Approximate total duration of the study: 18 months 
Number of groups to be studied: 2 groups 
Detailed description of the groups: 
Group 1-Patients presenting with STEMI, NSTEMI. 
Group 2- Age and sex matched patients coming to the hospital with non 
cardiac chest pain      
Sampling: 
Sample size of each group:  85 
Total sample size of the study: 170 
Scientific basis of sample size used in the study: 
n = ZS2[Zα+Zβ]2 
         (M1-M2)     
            M1=Mean platelet volume in ACS=11.44  (Randheer et al.10) 
M2=Mean platelet volume in ACS=9.91 
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S1=1.23 
S2=1.27 
Zα=1.64 
Zβ=0.84 
Power=80% 
Sample size=85 
Sampling technique used in the study:  Convenient  sampling 
Inclusion criteria: 
GROUP 1- 
1. Age-35- 75 years. 
2. Positive ECG findings. 
3. Troponin T positive. 
GROUP 2- 
1. Age 35-75 years 
2. No positive findings in ECG. 
3. Troponin T test negative. 
 Exclusion criteria: 
1. Critically ill patients (ACA associated with hepatic failure, renal failure, 
myeloproliferative disorder or malignancy). 
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2. Patients having platelet disorder such as thrombocytopenia or 
thrombocytosis. 
3. Patients with any bleeding disorder. 
4. Patients with any clotting disorder. 
5.  Patients on previous  anti platelet therapy. 
6. Patients on fibrinolytics. 
7. Patients on Anti cancer therapy. 
Procedure in detail: 
After acceptance of the protocol by the ethics committee an informed 
consent will obtained from those patients diagnosed with ACS presenting in the 
casualty or Medicine OPD of Sree Mookambika Institute of Medical Sciences 
who fulfil the criteria of inclusion and exclusion. 
History taking: 
Profoma is used for documenting age /sex /address / clinical 
information/symptoms/predisposing factors/and any previous history of 
treatment. 
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Collection of samples: 
2 ml of blood will be collected in an EDTA container  from the patient’s 
medial cubital vein on admission which should be from 6 hours from onset of 
chest pain. 
This sample will be immediately sent to the haematology unit of the 
Central Lab to obtain the platelet indices by 1) MINDRAY BC5300 & 2) 
Beckman Coulter Autoanalyser (reagent used: diluent). 
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RESULTS & ANALYSIS 
SOCIODEMOGRAPHIC CHARACTERISTICS  
AGE DISTRIBUTION 
The distribution of age in ACS patients ranges from 34 to 75 years. The 
mean age of study participants were 55.66 years (95% CI is 54.52, 56.68) and a 
SD of 9.967 years. 
The distribution of age in non ACS patients ranges from 34 to 74 years. 
The mean age of study participants were 56.35 years (95% CI is 54.327, 
58.373) and a SD of 9.518 years. 
Table 1:Distribution according to age of participants 
 
 
 
 
 
In ACS patients majority of them were 50-59 years of age group 
(34.1%), followed by 40-49 years of age group and 60-69 years of age group 
(27.1%). In non ACS patients majority of them were 60-69 years of age group 
(40%), followed by 50-59 years of age group (30.6%) and 40-49 years of age 
group (21.2%). 
Age characteristics 
ACS Non ACS 
Value Value 
Minimum 
Maximum 
Mean  
Standard deviation 
34 
75 
55.66 
9.967 
34 
74 
56.35 
9.518 
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Table 7:Distribution of family history 
Family 
history 
ACS Non ACS 
Frequency Percentage Frequency Percentage 
Present  
Not present 
Total  
24 
61 
85 
28.2 
71.8 
100 
20 
65 
85 
23.5 
76.5 
100 
 
In ACS patients only 28.2% (24) having family histories and in non 
ACS patients 23.5% (20) having family histories 
  
Results 
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TOTAL CHOLESTEROL  
The distribution of total cholesterol in ACS patients ranges from 145 to 
455. The mean cholesterol level of study participants were 266.33 with a SD of 
61.685. 
The distribution of total cholesterol in non ACS patients ranges from 
100 to 288. The mean cholesterol level of study participants were 167.68 with a 
SD of 39.402.  
Table 8:distribution of total cholesterol 1 
 
 
 
 
 
 
 
 
In ACS patients majority of them have high level of cholesterol (55.3%) 
followed by border line level of cholesterol (29.4%). In non ACS patients 
majority of them have desirable level of cholesterol (83.5%) followed by 
border line level of cholesterol (11.8%). 
 
Total cholesterol 
ACS Non ACS 
Value Value 
Minimum 
Maximum 
Mean  
Standard deviation 
145 
455 
266.33 
61.685 
100 
288 
167.68 
39.402 
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Table 10:Distribution of BMI 
 
 
 
 
 
 
 
 
In ACS patients majority of them have normal range of BMI (67%) 
followed by pre obese (31.8%). In ACS patients majority of them have normal 
range of BMI (91.8%) followed by 4.7% were under weight. 
 
 
 
 
 
 
 
 
BMI 
ACS Non ACS 
Value Value 
Minimum 
Maximum 
Mean  
Standard deviation 
20.2 
30.4 
23.95 
2.3 
17.5 
27 
21.57 
1.91 
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Table 12:Distribution of MPV 
 
 
 
 
 
 
 
 
PDW 
The distribution of PDW in ACS patients ranges from 12 to 23. The 
mean PDW of study participants were 19.134 with a SD of 2.153. 
The distribution of PDW in non ACS patients ranges from 9 to 23. The 
mean PDW of study participants were 13.611with a SD of 2.646.  
  
 
MPV 
ACS Non ACS 
Value Value 
Minimum 
Maximum 
Mean  
Standard deviation 
10.6 
14 
12.468 
0.714 
9.3 
14.3 
10.636 
0.895 
Results 
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Table 13:Distribution of PDW 
 
 
 
 
 
 
PCT 
The distribution of PCT in ACS patients ranges from 1.7 to 3.95. The 
mean PCT of study participants were 3.1 with a SD of 0.489. 
The distribution of PCT in non ACS patients ranges from 1.1 to 3.6. The 
mean PCT of study participants were 2.19 with a SD of 0.539.  
Table 14:Distribution of PCT 
 
 
 
 
 
 
 
PDW 
ACS Non ACS 
Value Value 
Minimum 
Maximum 
Mean  
Standard deviation 
12 
23 
19.134 
2.153 
9 
23 
13.611 
2.646 
 
PCT 
ACS Non ACS 
Value Value 
Minimum 
Maximum 
Mean  
Standard deviation 
1.7 
3.95 
3.1 
0.489 
1.1 
3.6 
2.19 
0.539 
Results 
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COMPARISON OF MPV, PDW, PCT BETWEEN ACS AND non ACS 
PATIENTS 
Students ‘t’ test used to compare the mean MPV, PDW, PCT between 
ACS and non ACS  patients. P value less than 0.05 is considered as significant. 
In this study it is found that there is significant difference in MPV, PDW, PCT 
in ACS and non ACS patients. 
Table :15 
 
  
Variable t-value p-value 
MPV 14.745 0.000* 
PDW 14.922 0.000* 
PCT 11.509 0.000* 
Results 
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Table 16: 
 χ2 value p value 
Age  
Gender 
DM 
Hypertension 
Smoking 
Family history 
Total cholesterol 
BMI 
4.151 
1.675 
4.618 
0.109 
13.55 
0.491 
82.731 
29.017 
0.394 
0.196 
0.032* 
0.742 
0.000* 
0.484 
0.000* 
0.000* 
   *p <0.05 is statistically significant  
 
FACTORS ASSOCIATED WITH ACS 
Chi-square test or Fisher’s Exact test is used to find out the factors 
associated ACS. p value less than 0.05 is considered as significant. In this study 
Education DM, smoking, total cholesterol and BMI (p<0.05) were associated 
with ACS. 
*p <0.05 is statistically significant 
Discussion 
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DISCUSSION 
The total number of subjects included in my study was 170.  Among 
those 170 subjects, 85 were cases (ACS) and 85 were controls (non ACS). 
In our study the age of the study population varies from 35-70 years.The 
mean age of study participants were 55.66 years (95% CI is 54.52, 56.68) and a 
SD of 9.967 years.The distribution of age in non ACS patients ranges from 34 
to 74 years. The mean age of study participants were 56.35 years (95% CI is 
54.327, 58.373) and a SD of 9.518 years. In ACS patients majority of them 
were 50-59 years of age group (34.1%), followed by 40-49 years of age group 
and 60-69 years of age group (27.1%). In non ACS patients majority of them 
were 60-69 years of age group (40%)by 50-59 years of age group (30.6%) 
.Shukri M Al-Saif , Khalid F. Al Habib, AnharUllah  had studied about age and 
relationship to acute coronary syndrome in a large Saudi population and found 
out that older patients have higher hospital mortality as they are treated less 
aggressively.37 
In our study in those with ACS  61.2% (52) were males and 38.8%  (33) 
were  females. In non ACS patients 70.6% (60) were males and 29.4% (25) 
were females. 
In ACS  patients 56.5% (48) had type -2 diabetes mellitus and in non 
ACS patients 40% (34) had type-2 diabetes mellitus. Where as in a study 
conducted by Laxman Dubey, Sogunuru Guruprasad, Gangapatnam 
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Subramanyam observed that in group of 223 patients more complex coronary 
lesions were seen in patients with type 2 diabetes mellitus.40 
In this study, ACS patients 69.4% (59) were hypertensive’s and 30.6% 
(26) were non hypertensives. In non ACS patients 67.1% (57) were 
hypertensives and 32.9% (28) were non hypertensives. 
In this study, in ACS patients 63.5% (54) were smokers and 36.5% (31) 
were non smokers. In non ACS patients only 35.3% (30) were smokers and 
64.7% (55) were non smokers.in a study conducted by Khaled Hbejan in 1107 
cases he found out that Myocardial infarction risk increased with increasing 
daily number of cigarettes smoked. The risk of an acute myocardial infarction 
doubled in smokers of 1 to 15 cigarettes a day.41 
Also the mean cholesterol level of study participants were 266.33 and 
distribution of total cholesterol in non ACS patients ranges from 100 to 288.In 
ACS patients majority of them have high level of cholesterol (55.3%). 
Whereas, the distribution of BMI in ACS patients ranges from 20.2 to 
30.4. The mean BMI of study participants were 23.95 with a SD of 2.3.The 
distribution of BMI in non ACS patients ranges from 17.5 to 27.There were 27 
patients who belonged to the pre obese group and al were in the group of cases. 
When compared to study done byJon Dooley, Anna Marie Chang in 
Pennsylvania in about 3946 patients it was observed thatalthough increased 
levels of obesity were associated with a greater number of cardiac risk factors, 
there was no difference in 30-day cardiovascular events between those 
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ofnormal weight and underweight , overweight , obese, or very obese. Those 
who were underweight were more likely to be readmitted within 30 days, and 
those who were very obese were less likely to be readmitted within30 days.42 
The distribution of MPV in ACS patients ranges from 10.6 to 14. The 
mean MPV of study participants were 12.468 with a SD of 0.714.The 
distribution of MPV in non ACS patients ranges from 9.3 to 14.3. It was found 
out there was significant association with MPV and ACS. Similarly  in a study 
byKruthika S Patil, S D Karchi in Banglore  have reported that patients with 
acute coronary syndromes had higher MPV when compared to NCCP group.43 
The distribution of PDW in ACS patients ranges from 12 to 23. The 
mean PDW of study participants were 19.134 with a SD of 2.153.The 
distribution of PDW in non ACS patients ranges from 9 to 23. The mean PDW 
of study participants were 13.611with a SD of 2.646.The present  study showed 
that there was significant association between Platelet Distribution Width and 
ACS.A cross sectional study done by IdarMappangara, Ali 
AsparMappahya, Sheila Witjaksonoin Indonesia ,there were significantly 
higher PDW (p=0.047) in STEACS group (13.7±2.0 fL) than in NSTEACS 
group (12.6±2.3 fL). There were a significant positive correlation between 
PDW .44 
The distribution of PCT in ACS patients ranges from 1.7 to 3.95. The 
distribution of PCT in non ACS patients ranges from 1.1 to 3.6. The mean PCT 
of study participants were 2.19 with a SD of 0.539. 
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Whereas in a cross-sectional study conducted byMehmet Serkan Cetin, 
ElifHandeOzcan Cetin, Ahmet Akdiconsisted 565 subjects which classified 
into three groups:group 1 (168 young patients with STEMI), group 2 (173 non-
young patients with STEMI), andgroup 3 (224 age-matched controls with 
angiographically normal coronary arteries).In Group 1, PDW and PCT were 
significantly higher than the other groups.45 
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CONCLUSION 
 Platelet indices in patients with ACS were significantly increased when 
compared to the normal population. 
 Diabetes, smoking, raised total cholesterol and BMI were also additional 
risk factors in the development of ACS. 
 There is no role of family history in the development of ACS as per my 
study. 
 More males presented with complaints of chest pain and were diagnosed 
to have ACS compared to females. 
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SUMMARY 
The WHO has drawn attention the fact that coronary artery disease is a 
modern epidemic more in geriatric population ie, people above 60 years of age. 
Large increase in coronary artery disease has been projected and now it is the 
most common cause of death. 
Previous data suggests that only 1/3rd of chest pain cases require 
emergency care and hospitalization but in the absence of segregation of these 
cases in the beginning, physicians over admit such patients and it burns out the 
precious resources in the public  setup . Further it may reduce the quality of 
care for those who actually require it. 
Platelet indices is a simple and economic laboratory measurement (less 
costly and can be done  when a complete blood count is already requested), I 
suggest that it might be useful as an assisting rule-out test in conjunction with 
other conventional biochemical cardiac markers in the early prediction of the 
risk of ACS in patients admitted to the emergency department. 
The study was a hospital based observational study conducted in Sree 
Mookambika Institute of Medical Sciences, Kulashekharam, KanyaKumari 
district. 
The total number of subjects included in the study was 170.among those 
85 were cases (with chest pain diagnosed to have ACS) and the rest were 
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controls (patients with non cardiac chest pain).In my study the age of the 
population varies from 35 to 70 years .In my studyThe mean age of study 
participants with ACS and non ACS was 55.66 years and 56.35 years 
respectively.In ACS patients 61.2% (52) were males and 38.8% (33) were  
females. In non ACS patients 70.6% (60) were males and 29.4% (25) were 
females. Among the   cases 54 had the habit of smoking whereas among 
controls only 30 patients had the habit.In ACS  patients 56.5% (48) have 
diabetes mellitus and in non ACS patients 40% (34) have diabetes mellitus. 
Only 24 patients among the cases had a positive family history,similarly 
only 20 patients had a positive family history in  control group also.In  those   
patients  who had ACS majority of them have normal range of BMI (67%) 
followed by pre obese (31.8%). In non  ACS patients majority of them have 
normal range of BMI (91.8%) followed by 4.7% were under weight. High 
cholesterol levels were also seen to be associated with ACS as 47 people out 
the cases were found to have high cholesterol levels compared to the controls  
where 4 subjects had only higher levels of cholesterol. 
The mean BMI of those who presented with ACS was 23.95  whereas 
the mean BMI of patients with  non cardiac chest pain was  21.57 . 
The mean MPV of study participants  who presented with ACSwere 
12.468. 
Summary 
 
 
74 
 
While observing  the mean MPV of study participants  without ACS it 
was 10.636 .so there was significant correlation between MPV and ACS. 
In the case of the next platelet parameter PDW it was found that in 
patients who presented with ACS the mean value was 19.134.. The mean PDW 
of study participants were 13.611.Similarly in the case of the plateletcrit the 
mean PCT of study participants with ACS was 3.1 .The distribution of PCT in 
non ACS patients ranges from 1.1 to 3.6. The mean PCT of study participants 
were 2.19 with a SD of 0.539. Hence in this study it was observed that there is 
significant difference in MPV, PDW, PCT in ACS and non ACS 
patientsanother observation is thatin this study  DM, smoking, total cholesterol 
and BMI (p<0.05) were associated with ACS. 
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LIMITATIONS 
The study group was small, that is, the study group of 150 patients could 
not be extrapolated to the general population. 
Serum MPV, PDW. PCT, and other tests like serum cholesterol was 
taken only once so their variability as time passed was not studied which made 
us unable to account for intra individual variability. 
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ANNEXURE – II 
LIST OF ABBREVIATIONS USED 
 
 ACS - Acute Coronary Syndrome 
 BMI - Body Mass Index 
 MPV - Mean Platelet Volume 
 PDW - Platelet Distribution  Width 
 PCT - Plateletcrit 
 SPSS -       Statistical  Packagefor SocialSciences  
 CVD - Cardiovascular Disease 
 FGF - Fibroblast Growth Factor 
 WHO - World Health Organisation 
 IHD - Ischaemic Heart Disease. 
 DALY - Disability Adjusted Life Years 
 LMIC - Low  Medium Income Countries 
 HIC - High Income Countries 
 AMI - Acute Myocardial Infarction 
 STEMI - ST Elevation MI 
 NSTEMI - Non ST Elevation MI 
 NSTE ACS - Non ST Elevation Acute Coronarysyndrome 
 UA - Unstable angina 
 TIA - Transient Ischaemic Attack 
 LDL - Low Density Lipoprotein 
 ECG - Electrocardiography 
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 LBBB - Left Bundle Branch Block 
 VWF - Von Willebrands Factor 
 EGF - Epidermal Growth  Factor 
 SD - Standard Deviation 
 DM - Diabetes Mellitus 
 UFH -  Unfractionated Heparin 
 LMWH -  Low Molecular Weight Heparin 
 PCI - Percutaneous Coronary Intervention 
 NTG - Nitroglycerin 
 NSAID - Non Steroidal Anti inflammatory Drugs\ 
 ACE - Acetyl Cholinesterase  
 ARB - Angiotensin2 receptor Blocker 
 CCU - Coronary Care Unit 
 ACC/AHA - American College Cardiology/American Heart 
Association 
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ANNEXURE – III 
 
CONSENT FORM 
PART 1 OF 2 
INFORMATION FOR PARTICIPANTS OF THE STUDY 
Dear Participants, 
 We welcome you and thank you for your keen interest in participation in this 
research project. Before you participate in this study, it is important for you to 
understand why this research is being carried out. This form will provide you all the 
relevant details of this research. It will explain the nature, the purpose, the benefits, 
the risks, the discomforts, the precautions and the information about how this project 
will be carried out. It is important that you read and understand the contents of the 
form carefully. This form may contain certain scientific terms and hence, if you have 
any doubts or if you want more information, you are free to ask the study personnel or 
the contact person mentioned below before you give your consent and also at any time 
during the entire course of the project. 
 
1.  Name of the Principal Investigator : Dr.AswathiHarikumar 
  General Medicine Post Graduate 
  Department of General Medicine 
  SreeMookambika Institute of Medical Sciences 
 
2.  Name of the Guide : Dr. Kaniraj Peter 
  HOD,Professor, 
   Department of General Medicine 
  SreeMookambika Institute of Medical Science 
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3.  Name of the Co-Guide : Dr. Ajay kumar 
  Professor 
   Department of Cardiology, 
  SreeMookambika Institute of Medical Sciences 
 
4.  Institute : SreeMookambika Institute of  
  Medical sciences, 
  Kulashekharam, 
  Kanyakumari district-629161 
  Tamilnadu 
 
5. Title of the study:    
ASSOCIATION BETWEEN PLATELET INDICES AND ACUTE 
CORONARY SYNDROME IN A TERTIARY CARE CENTRE –A 
COMPARATIVE STUDY 
1. Background information:  
Acute Coronary syndrome manifests as stable angina pectoris ,unstable angina 
pectoris, acute myocardial ishcaemia (STEMI and NSTEMI) which are the most 
common causes of morbidity and mortality .In this scenario platelets play an 
important role in the pathogenesis of Acute Coronary syndrome. The present cardiac 
markers are not sufficiently sensitive at an early stage of ACS. That’s why an early 
reliable marker such as platelet indices is needed for the accurate diagnosis of ACS.   
7.  Aims and Objectives: 
To find out and compare the values of platelet indices between ACS and non 
ACS patients. 
8.  Scientific justification of the study: 
Previous data suggest that only one-fifth of chest pain cases require 
emergency care and  hospitalization but in the absence of segregation of these cases at 
he beginning physicians tend to overadmit such patients. It burns out the precious 
resources of resource poor public set up. Thus it will reduce the quality of care of 
those who actually require it .Moreover, a study of this topic has not  been  performed 
in the Kanyakumari district of Tamilnadu. 
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9.  Procedure for the study: 
The study is to be carried out at SreeMookambika Institute of  Medical 
Sciences. Relavant clinical and demographic data will be obtained from the patient. 
Will document the age/sex/address/clinical information/symptoms/. 
Predisposing factors and any previous history of treatment. 
Blood sample will be collected from the patient on admission which should be 
6 hours from the onset of chest pain. 
This sample will be immediately sent toHaematology unit of the Central lab to 
obtain the platelet indices by   (i)MindrayBC and(ii) Beckman Coulter Autoanalyzer  
and reagent used is diluent. 
10.  Expected risks for the participants: No risk 
11. Expected benefits of research for the participants: 
These markers can be used to detect   an impending  major vascular event of 
Acute Coronary  Syndrome and early anti-platelet therapy can be initiated early . 
12. Maintenance of Confidentiality: All data collected for the study will be 
maintained confidentially and would reflect on general statistical analysis only,would 
not reveal any personal details. 
13. Why have I been chosen to be in this study? 
1. You have been found to have  fulfilled the inclusion and exclusion  criteria of 
selection. 
2. You are ready to give consent. 
14. How many people will be in the study? 170 
15.  Agreement of Compensation to the participants (In case of a study related 
injury): NA 
16.  Anticipated prorated payment, if any, to the Participant (s) of the study:NA 
17. Can I withdraw from the study at any time during the study period:Yes 
18.  If there is any new findings/ information, would I be informed?  Yes 
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19.  Expected duration of the Participant’s participation in the study  :1 visit 
20.  Any other pertinent information:No 
21. Whom do I contact for further information? Dr.AswathiHarikumar 
 
 
 
 
 
 
 
 
        
Place:      
 
 
 
Signature of Principal Investigator 
Date: 
 
 
 
Signature of the Participant 
 
 
 
 
For any study related queries, you are free to contact 
 
Dr Aswathi Harikumar 
General Medicine Post Graduate 
Department of General Medicine 
SreeMookambika Institute of Medical Sciences 
Mobile No. 9585953080 
aswathi.harikumar@gmail.com 
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CONSENT FORM 
PART 2 OF 2 
PARTICIPANTS CONSENT FORM 
The details of the study have been explained to me in writing and the details 
have been fully explained to me. I am aware that the results of the study may not be 
directly beneficial to me but will help in the advancement of medical sciences. I 
confirm that I have understood the study and had the opportunity to ask questions. I 
understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without the medical care that will 
normally be provided by the hospital being affected. I agree not to restrict the use of 
any data or results that arise from this study provided such a use is only for scientific 
purpose(s). I have been given an information sheet giving details of the study. I fully 
consent to participate in the study titled ‘Association between platelet indices and 
Acute Coronary Syndrome in a tertiary care centre –A comparative study’ 
Serial no/Reference no: 
 
Name of the Participant:    Address of the Participant: 
 
Contact number of the Participant: 
 
  Signature/Thumb impression of the participant/Legal guardian  
 
Date:      Witnesses: 
 
Place       1. 
 
2.  
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ANNEXURE – IV 
Date:          SL.NO 
Place: 
CASE RECORD FORM  
AGE:                  GENDER: 
OCCUPATION: 
SMOKER:                                                   ALCOHOLIC: 
HYPERTENSION:                                     DIABETIC: 
FAMILY HISTORY: 
ANTI- PLATELET  THERAPY:                BLEEDING OR CLOTTING 
DISORDERS: 
MALIGNANCY:                                          MYELOPROLIFERATIVE 
DISORDERS: 
ON EXAMINATION 
WEIGHT:                      HEIGHT: 
 
PR:                                       BP: 
 
INVESTIGATIONS 
CBC: 
MPV:           PDW :                PCT: 
TOTAL CHOLESTEROL: 
ECG: 
TROPONIN T: 
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ANNEXURE – V 
MASTER CHART 
AGE gender DM HTN smoking 
total 
cho BMI familyh/o ECG  trop t MPV PDW PCT 
45 1 1 1 1 150 25.4 2 1 1 13.7 17 2.05 
46 1 2 2 2 300 24 2 2 1 12 20 2.06 
50 1 2 1 1 245 21 2 3 1 12.9 12 3 
54 2 2 1 2 300 26 2 2 1 11.9 13 2.9 
60 2 1 1 2 134 20 2 3 2 9.7 12 1.5 
45 1 1 2 2 345 27.6 2 1 1 12 22 2.9 
56 1 1 2 1 230 23.2 1 2 1 12.3 21 3.12 
64 1 2 2 2 245 23 1 1 1 12.5 20 2.88 
62 2 2 2 2 234 20 2 3 2 10.3 14 1.2 
49 2 2 1 2 345 27.6 2 1 1 12.8 19 3.01 
50 1 2 1 1 321 25 2 2 1 11.8 18 2.9 
67 1 2 1 1 234 24.6 2 2 1 11.8 21 3.5 
58 1 1 1 1 347 22 2 1 1 13.4 22 3.2 
49 1 1 1 1 277 26 2 3 2 10.5 19 1.6 
67 1 1 1 1 255 22.6 2 2 1 13.2 13 1.7 
66 1 2 1 1 320 25 2 2 1 11.7 18 3.4 
55 2 2 1 2 145 20 2 3 2 11.5 9 1.4 
50 1 2 2 2 200 21.7 1 2 1 11.3 19.5 2.2 
47 1 2 1 2 400 27.5 1 1 1 11.8 20.5 3.5 
66 2 2 1 2 311 24.7 1 1 1 12.4 21 3.9 
             
Annexure 
 
ii 
 
41 1 2 1 1 345 23.4 1 2 1 12.2 19 3.8 
53 1 1 1 1 234 20.8 1 1 1 11.7 13 3.7 
58 1 1 1 1 256 22 1 3 2 10.4 14 2.1 
64 2 2 2 2 237 21 2 2 1 13.4 20 2.6 
63 2 2 2 2 211 23.8 2 3 1 13.2 18 2.8 
55 2 2 2 2 222 21 2 2 1 11.5 18.5 3 
44 1 1 2 2 331 26.2 2 1 1 12.5 17.6 2.95 
45 1 1 1 1 123 20.1 2 3 2 10.3 15 2.1 
39 1 1 1 2 222 21.2 2 3 2 11.3 16 1.3 
45 1 1 1 1 209 19.6 2 3 2 10.9 19 1.8 
66 2 1 1 2 165 20.7 2 3 2 10 16 2.5 
66 1 1 1 1 145 23 2 2 1 13.2 19 2.05 
59 1 2 1 1 165 19 2 3 2 12 16 2.95 
45 1 2 2 1 300 21 2 2 1 11.5 20 3.95 
47 2 1 2 2 241 23.6 1 2 1 12.9 21 3.1 
68 2 2 2 2 254 22.3 1 3 2 13.4 23 3.3 
62 1 2 1 2 266 24.4 2 1 1 12.7 20.5 2.99 
64 1 2 1 2 288 22 2 3 2 11.5 11 2.6 
53 1 1 1 2 122 18.7 2 3 2 11.4 12 2.88 
50 1 1 1 2 156 19.7 2 3 2 11.3 13.5 2.7 
39 2 1 1 2 170 21 2 3 2 10.3 14.6 2.6 
45 1 1 2 1 190 20.3 2 3 2 11.1 13 2.2 
65 1 2 1 1 187 20.9 2 3 2 10.4 14 2.4 
40 1 2 2 2 145 19.2 2 3 2 10.3 15.6 2.2 
47 2 2 1 2 300 22.3 2 2 1 12.3 19.6 3.7 
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44 2 2 2 2 320 23.6 2 1 1 12.5 20 3.8 
54 1 2 1 2 200 22.6 2 3 2 9.7 15 2.2 
45 1 2 2 2 215 20.1 2 3 2 9.8 12 2.2 
67 1 1 1 1 231 21.8 2 2 1 14 18.5 3.2 
70 2 1 2 2 300 24.6 2 2 1 12.4 17 3.1 
38 1 1 1 2 211 22.3 1 2 1 13.4 19 3.9 
67 1 1 1 1 165 20.4 1 2 1 11.6 17 3.7 
56 2 1 1 2 159 20.8 1 3 2 9.9 13 2.6 
34 1 1 1 2 288 25.9 1 1 1 11.4 18.5 2.7 
65 2 1 1 2 111 18.7 1 3 2 10 14 2 
66 1 1 2 2 133 23.4 1 3 2 10.1 16 1.9 
34 1 1 2 1 155 21.5 2 3 2 11.1 12.6 1.3 
45 1 1 2 2 122 23 2 3 2 11.5 17 1.1 
65 2 2 1 2 176 22 2 2 1 12.6 17 1.9 
74 1 1 1 2 156 23 2 3 2 11.5 15 1.2 
54 1 2 1 1 123 21 2 3 2 11.7 14 1.9 
55 2 1 1 2 144 24 2 3 2 11.3 11 1.8 
44 2 2 1 2 211 23 2 2 1 12.2 17.5 3.2 
34 1 1 1 1 222 22 2 3 2 10.5 14 2.2 
59 1 2 1 1 234 25.6 2 1 1 12.8 17 2.7 
71 1 1 2 2 256 23 2 2 1 10.6 15 2.2 
37 2 2 2 2 300 27.7 2 1 1 12.9 18 3.2 
65 1 1 2 2 344 25.7 2 2 1 13.11 18.7 3.1 
57 1 2 2 1 455 26 2 1 1 12.9 20 3.3 
69 1 1 1 1 344 24.5 1 2 1 11.9 18 2.9 
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59 1 1 1 1 277 23 2 1 1 12 17 2.56 
67 2 1 1 2 344 26 2 2 1 12 19 2.9 
45 2 2 1 2 233 23 2 2 1 13.5 18.5 3.1 
67 1 2 1 2 366 24.5 2 2 1 13.6 17 3.2 
55 1 1 1 2 233 22 2 2 1 12.6 21 3.3 
58 1 2 1 2 256 23 2 1 1 11.7 18.5 3.4 
54 2 1 1 2 333 25.5 2 1 1 12.8 17 3.5 
45 1 2 2 2 216 23 1 1 1 12.4 19 2.2 
43 1 1 2 2 219 22 1 3 2 11.3 13 2.5 
49 1 2 2 1 333 24 1 1 1 11.4 16.7 3.5 
50 1 1 2 1 124 19.7 1 3 2 9.5 10 2.1 
53 1 2 1 1 156 20.2 2 3 2 9.8 10.5 2.4 
64 2 1 1 2 176 20.8 1 3 2 9.5 11 2.05 
67 2 1 1 2 145 19.4 2 3 2 10.8 16 1.7 
55 1 1 1 2 123 21 2 3 2 10.3 19 1.8 
75 1 2 1 2 234 22 2 2 1 12.3 18 3.2 
56 1 2 1 2 125 20 2 3 2 10.5 15 2.5 
66 1 2 2 1 100 23.3 2 3 2 10.6 14 2.3 
54 1 2 2 1 167 23 2 3 2 10.5 17 2.2 
58 2 2 2 2 176 21 2 3 2 10.3 16 2.1 
68 2 1 2 2 123 19.8 2 3 2 9.3 17 1.7 
45 2 1 2 2 145 18.4 2 3 2 11.2 12 1.8 
49 1 1 1 2 198 19.3 2 3 2 11.9 15 1.33 
59 1 2 1 2 187 20.2 2 2 1 11.9 19 2.7 
60 1 2 1 2 176 23.9 2 3 2 10.2 18.5 2.3 
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61 1 2 1 2 156 24 2 3 2 9.8 15 2.8 
66 1 2 1 1 144 24.4 2 3 2 9.9 11 2.8 
68 1 1 1 1 199 21.1 2 3 2 10.9 12 2.1 
46 1 1 1 1 188 22 2 3 2 11.4 15 2.9 
75 1 1 1 1 233 20.5 2 2 1 12.1 19 3.3 
49 2 1 2 2 266 23 1 2 1 14 17 3.1 
56 1 1 1 1 254 28 1 2 1 13.5 20 3.5 
57 2 2 2 2 188 20.9 1 2 1 12 21 3.8 
67 2 2 1 2 155 23 1 3 2 10.3 14 2.7 
64 1 2 2 1 177 21.8 1 3 2 11.9 12 2.6 
62 1 2 1 2 233 23 1 2 1 13.12 19 3.1 
60 1 2 2 2 111 21.9 2 3 2 9.9 16 2.7 
50 2 2 1 2 109 20.3 2 3 2 10.3 14 2.1 
67 1 1 1 2 200 21.1 2 3 2 10 10 1.9 
45 1 1 1 2 277 20.9 2 2 1 13.2 19.5 3.6 
55 1 1 1 1 234 29.4 2 1 1 12.7 20 3.2 
44 2 1 1 2 344 27.4 2 2 1 12.12 22 3.21 
36 2 1 1 2 211 23.3 2 1 1 13.4 21 3.6 
46 1 2 1 1 222 22.2 2 3 2 14.3 17.7 3.6 
45 1 2 1 1 122 21.9 2 3 2 12 16 1.9 
70 1 2 1 2 134 23 2 3 2 11.4 12 1.88 
67 2 2 1 2 156 21.8 2 3 2 11.3 13 2.44 
68 1 2 1 2 176 22.7 2 3 2 10.2 13 2.56 
65 1 2 2 2 144 21.7 2 3 2 9.5 12 2.5 
56 1 2 2 2 155 23.7 2 3 2 9.5 16 2.33 
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57 2 1 1 2 187 24 2 2 1 12.3 20 3.6 
58 2 1 1 2 197 21.9 1 2 1 11.8 22 3.2 
59 1 1 1 1 197 27 1 2 1 11.8 21 3.2 
46 1 1 1 1 123 23.9 1 3 2 9.9 12 2.2 
56 1 2 1 1 145 21.8 2 3 2 9.5 13 2.4 
54 2 2 1 2 154 22.8 2 3 2 10.5 11 2.77 
53 1 2 1 1 222 23.1 2 2 1 13 19 3.9 
65 2 2 1 2 155 22.7 2 3 2 11.3 11 2.99 
64 1 2 1 1 211 27 2 3 2 11.2 10 2.11 
48 1 1 2 2 200 23.8 2 2 1 11.7 19.5 2.95 
56 1 1 2 1 166 24.9 2 3 2 10.9 11 2.1 
67 1 1 2 2 156 18.4 2 3 2 9.9 10 1.9 
68 1 1 2 1 198 19.4 1 3 2 9.9 15 2.37 
66 2 1 1 2 178 20.5 1 3 2 9.8 12 2.75 
45 2 2 1 2 109 21 1 3 2 11.4 13 1.23 
55 2 1 1 2 177 24 1 3 2 11.4 11 1.4 
44 1 2 1 1 234 23.6 2 1 1 11.8 19 2.79 
65 1 2 1 1 298 25.5 2 1 1 11.4 20 2.7 
58 2 2 1 2 222 30.4 2 2 1 11.9 22 3.45 
67 2 1 1 2 322 27.7 2 2 1 12.5 22 3.7 
45 2 1 1 2 377 24.9 2 2 1 12.2 20.5 3.55 
56 1 1 1 2 344 23 2 2 1 12.6 22 3.2 
48 1 2 1 2 222 24.4 2 3 2 10.8 14 2.05 
59 1 1 2 2 111 22.2 2 3 2 10.8 12 2.23 
39 2 2 2 2 211 23.3 2 3 2 11.1 9 2.9 
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56 2 1 2 2 266 21.9 2 2 1 12.8 18 2.5 
67 2 2 2 2 333 24.4 2 1 1 13 19 2.99 
68 2 1 2 2 156 26.6 1 3 2 11.3 11 3.5 
53 2 2 2 2 166 20.8 1 1 1 12.6 19 2.87 
54 2 1 1 2 155 22.4 1 3 2 9.5 14 2.13 
64 1 2 1 1 132 21 1 3 2 9.6 14 2.1 
60 1 2 1 1 176 18.5 2 3 2 9.6 16 2.9 
62 1 2 1 1 198 19.5 2 3 2 9.6 13 1.76 
56 1 1 1 1 176 17.5 2 3 2 9.5 9 1.95 
59 1 1 1 2 187 20.1 2 3 2 11.3 10 2.55 
66 1 2 1 2 155 22.4 1 3 2 10.3 13 1.1 
45 1 2 1 2 154 23.8 1 3 2 9.5 16 1.55 
56 1 1 1 2 344 21.1 1 1 1 11.5 22 3.12 
67 2 2 1 2 238 25.5 1 2 1 13.5 21 3.2 
75 2 2 1 2 200 25 1 2 1 13.2 20.8 3.56 
47 2 1 1 2 276 28 2 2 1 12.5 21 3.44 
68 1 2 1 1 265 26.6 2 2 1 13.5 21 3.11 
67 1 1 1 1 230 21.8 2 1 1 12.8 23 2.99 
39 1 2 1 1 300 25.5 2 1 1 12 20 3.22 
49 1 1 1 1 231 22.9 2 2 1 11.8 19 3.65 
59 1 1 2 1 199 22.9 2 3 2 11.5 10 2.4 
66 1 1 2 2 176 21.1 2 3 2 10.9 11 2.85 
55 2 1 2 2 300 26.9 2 1 1 12.7 22 2.77 
56 2 2 1 2 222 20.5 2 1 1 13.7 20 2.6 
 
AGE gender DM HTN smoking total cho BMI familyh/o ECG  trop t MPV PDW PCT
45 1 1 1 1 150 25.4 2 1 1 13.7 17 2.05
46 1 2 2 2 300 24 2 2 1 12 20 2.06
50 1 2 1 1 245 21 2 3 1 12.9 12 3
54 2 2 1 2 300 26 2 2 1 11.9 13 2.9
60 2 1 1 2 134 20 2 3 2 9.7 12 1.5
45 1 1 2 2 345 27.6 2 1 1 12 22 2.9
56 1 1 2 1 230 23.2 1 2 1 12.3 21 3.12
64 1 2 2 2 245 23 1 1 1 12.5 20 2.88
62 2 2 2 2 234 20 2 3 2 10.3 14 1.2
49 2 2 1 2 345 27.6 2 1 1 12.8 19 3.01
50 1 2 1 1 321 25 2 2 1 11.8 18 2.9
67 1 2 1 1 234 24.6 2 2 1 11.8 21 3.5
58 1 1 1 1 347 22 2 1 1 13.4 22 3.2
49 1 1 1 1 277 26 2 3 2 10.5 19 1.6
67 1 1 1 1 255 22.6 2 2 1 13.2 13 1.7
66 1 2 1 1 320 25 2 2 1 11.7 18 3.4
55 2 2 1 2 145 20 2 3 2 11.5 9 1.4
50 1 2 2 2 200 21.7 1 2 1 11.3 19.5 2.2
47 1 2 1 2 400 27.5 1 1 1 11.8 20.5 3.5
66 2 2 1 2 311 24.7 1 1 1 12.4 21 3.9
41 1 2 1 1 345 23.4 1 2 1 12.2 19 3.8
53 1 1 1 1 234 20.8 1 1 1 11.7 13 3.7
58 1 1 1 1 256 22 1 3 2 10.4 14 2.1
64 2 2 2 2 237 21 2 2 1 13.4 20 2.6
63 2 2 2 2 211 23.8 2 3 1 13.2 18 2.8
55 2 2 2 2 222 21 2 2 1 11.5 18.5 3
44 1 1 2 2 331 26.2 2 1 1 12.5 17.6 2.95
45 1 1 1 1 123 20.1 2 3 2 10.3 15 2.1
39 1 1 1 2 222 21.2 2 3 2 11.3 16 1.3
45 1 1 1 1 209 19.6 2 3 2 10.9 19 1.8
66 2 1 1 2 165 20.7 2 3 2 10 16 2.5
66 1 1 1 1 145 23 2 2 1 13.2 19 2.05
59 1 2 1 1 165 19 2 3 2 12 16 2.95
45 1 2 2 1 300 21 2 2 1 11.5 20 3.95
47 2 1 2 2 241 23.6 1 2 1 12.9 21 3.1
68 2 2 2 2 254 22.3 1 3 2 13.4 23 3.3
62 1 2 1 2 266 24.4 2 1 1 12.7 20.5 2.99
64 1 2 1 2 288 22 2 3 2 11.5 11 2.6
53 1 1 1 2 122 18.7 2 3 2 11.4 12 2.88
50 1 1 1 2 156 19.7 2 3 2 11.3 13.5 2.7
39 2 1 1 2 170 21 2 3 2 10.3 14.6 2.6
45 1 1 2 1 190 20.3 2 3 2 11.1 13 2.2
65 1 2 1 1 187 20.9 2 3 2 10.4 14 2.4
40 1 2 2 2 145 19.2 2 3 2 10.3 15.6 2.2
47 2 2 1 2 300 22.3 2 2 1 12.3 19.6 3.7
44 2 2 2 2 320 23.6 2 1 1 12.5 20 3.8
54 1 2 1 2 200 22.6 2 3 2 9.7 15 2.2
45 1 2 2 2 215 20.1 2 3 2 9.8 12 2.2
67 1 1 1 1 231 21.8 2 2 1 14 18.5 3.2
70 2 1 2 2 300 24.6 2 2 1 12.4 17 3.1
38 1 1 1 2 211 22.3 1 2 1 13.4 19 3.9
67 1 1 1 1 165 20.4 1 2 1 11.6 17 3.7
56 2 1 1 2 159 20.8 1 3 2 9.9 13 2.6
34 1 1 1 2 288 25.9 1 1 1 11.4 18.5 2.7
65 2 1 1 2 111 18.7 1 3 2 10 14 2
66 1 1 2 2 133 23.4 1 3 2 10.1 16 1.9
34 1 1 2 1 155 21.5 2 3 2 11.1 12.6 1.3
45 1 1 2 2 122 23 2 3 2 11.5 17 1.1
65 2 2 1 2 176 22 2 2 1 12.6 17 1.9
74 1 1 1 2 156 23 2 3 2 11.5 15 1.2
54 1 2 1 1 123 21 2 3 2 11.7 14 1.9
55 2 1 1 2 144 24 2 3 2 11.3 11 1.8
44 2 2 1 2 211 23 2 2 1 12.2 17.5 3.2
34 1 1 1 1 222 22 2 3 2 10.5 14 2.2
59 1 2 1 1 234 25.6 2 1 1 12.8 17 2.7
71 1 1 2 2 256 23 2 2 1 10.6 15 2.2
37 2 2 2 2 300 27.7 2 1 1 12.9 18 3.2
65 1 1 2 2 344 25.7 2 2 1 13.11 18.7 3.1
57 1 2 2 1 455 26 2 1 1 12.9 20 3.3
69 1 1 1 1 344 24.5 1 2 1 11.9 18 2.9
59 1 1 1 1 277 23 2 1 1 12 17 2.56
67 2 1 1 2 344 26 2 2 1 12 19 2.9
45 2 2 1 2 233 23 2 2 1 13.5 18.5 3.1
67 1 2 1 2 366 24.5 2 2 1 13.6 17 3.2
55 1 1 1 2 233 22 2 2 1 12.6 21 3.3
58 1 2 1 2 256 23 2 1 1 11.7 18.5 3.4
54 2 1 1 2 333 25.5 2 1 1 12.8 17 3.5
45 1 2 2 2 216 23 1 1 1 12.4 19 2.2
43 1 1 2 2 219 22 1 3 2 11.3 13 2.5
49 1 2 2 1 333 24 1 1 1 11.4 16.7 3.5
50 1 1 2 1 124 19.7 1 3 2 9.5 10 2.1
53 1 2 1 1 156 20.2 2 3 2 9.8 10.5 2.4
64 2 1 1 2 176 20.8 1 3 2 9.5 11 2.05
67 2 1 1 2 145 19.4 2 3 2 10.8 16 1.7
55 1 1 1 2 123 21 2 3 2 10.3 19 1.8
75 1 2 1 2 234 22 2 2 1 12.3 18 3.2
56 1 2 1 2 125 20 2 3 2 10.5 15 2.5
66 1 2 2 1 100 23.3 2 3 2 10.6 14 2.3
54 1 2 2 1 167 23 2 3 2 10.5 17 2.2
58 2 2 2 2 176 21 2 3 2 10.3 16 2.1
68 2 1 2 2 123 19.8 2 3 2 9.3 17 1.7
45 2 1 2 2 145 18.4 2 3 2 11.2 12 1.8
49 1 1 1 2 198 19.3 2 3 2 11.9 15 1.33
59 1 2 1 2 187 20.2 2 2 1 11.9 19 2.7
60 1 2 1 2 176 23.9 2 3 2 10.2 18.5 2.3
61 1 2 1 2 156 24 2 3 2 9.8 15 2.8
66 1 2 1 1 144 24.4 2 3 2 9.9 11 2.8
68 1 1 1 1 199 21.1 2 3 2 10.9 12 2.1
46 1 1 1 1 188 22 2 3 2 11.4 15 2.9
75 1 1 1 1 233 20.5 2 2 1 12.1 19 3.3
49 2 1 2 2 266 23 1 2 1 14 17 3.1
56 1 1 1 1 254 28 1 2 1 13.5 20 3.5
57 2 2 2 2 188 20.9 1 2 1 12 21 3.8
67 2 2 1 2 155 23 1 3 2 10.3 14 2.7
64 1 2 2 1 177 21.8 1 3 2 11.9 12 2.6
62 1 2 1 2 233 23 1 2 1 13.12 19 3.1
60 1 2 2 2 111 21.9 2 3 2 9.9 16 2.7
50 2 2 1 2 109 20.3 2 3 2 10.3 14 2.1
67 1 1 1 2 200 21.1 2 3 2 10 10 1.9
45 1 1 1 2 277 20.9 2 2 1 13.2 19.5 3.6
55 1 1 1 1 234 29.4 2 1 1 12.7 20 3.2
44 2 1 1 2 344 27.4 2 2 1 12.12 22 3.21
36 2 1 1 2 211 23.3 2 1 1 13.4 21 3.6
46 1 2 1 1 222 22.2 2 3 2 14.3 17.7 3.6
45 1 2 1 1 122 21.9 2 3 2 12 16 1.9
70 1 2 1 2 134 23 2 3 2 11.4 12 1.88
67 2 2 1 2 156 21.8 2 3 2 11.3 13 2.44
68 1 2 1 2 176 22.7 2 3 2 10.2 13 2.56
65 1 2 2 2 144 21.7 2 3 2 9.5 12 2.5
56 1 2 2 2 155 23.7 2 3 2 9.5 16 2.33
57 2 1 1 2 187 24 2 2 1 12.3 20 3.6
58 2 1 1 2 197 21.9 1 2 1 11.8 22 3.2
59 1 1 1 1 197 27 1 2 1 11.8 21 3.2
46 1 1 1 1 123 23.9 1 3 2 9.9 12 2.2
56 1 2 1 1 145 21.8 2 3 2 9.5 13 2.4
54 2 2 1 2 154 22.8 2 3 2 10.5 11 2.77
53 1 2 1 1 222 23.1 2 2 1 13 19 3.9
65 2 2 1 2 155 22.7 2 3 2 11.3 11 2.99
64 1 2 1 1 211 27 2 3 2 11.2 10 2.11
48 1 1 2 2 200 23.8 2 2 1 11.7 19.5 2.95
56 1 1 2 1 166 24.9 2 3 2 10.9 11 2.1
67 1 1 2 2 156 18.4 2 3 2 9.9 10 1.9
68 1 1 2 1 198 19.4 1 3 2 9.9 15 2.37
66 2 1 1 2 178 20.5 1 3 2 9.8 12 2.75
45 2 2 1 2 109 21 1 3 2 11.4 13 1.23
55 2 1 1 2 177 24 1 3 2 11.4 11 1.4
44 1 2 1 1 234 23.6 2 1 1 11.8 19 2.79
65 1 2 1 1 298 25.5 2 1 1 11.4 20 2.7
58 2 2 1 2 222 30.4 2 2 1 11.9 22 3.45
67 2 1 1 2 322 27.7 2 2 1 12.5 22 3.7
45 2 1 1 2 377 24.9 2 2 1 12.2 20.5 3.55
56 1 1 1 2 344 23 2 2 1 12.6 22 3.2
48 1 2 1 2 222 24.4 2 3 2 10.8 14 2.05
59 1 1 2 2 111 22.2 2 3 2 10.8 12 2.23
39 2 2 2 2 211 23.3 2 3 2 11.1 9 2.9
56 2 1 2 2 266 21.9 2 2 1 12.8 18 2.5
67 2 2 2 2 333 24.4 2 1 1 13 19 2.99
68 2 1 2 2 156 26.6 1 3 2 11.3 11 3.5
53 2 2 2 2 166 20.8 1 1 1 12.6 19 2.87
54 2 1 1 2 155 22.4 1 3 2 9.5 14 2.13
64 1 2 1 1 132 21 1 3 2 9.6 14 2.1
60 1 2 1 1 176 18.5 2 3 2 9.6 16 2.9
62 1 2 1 1 198 19.5 2 3 2 9.6 13 1.76
56 1 1 1 1 176 17.5 2 3 2 9.5 9 1.95
59 1 1 1 2 187 20.1 2 3 2 11.3 10 2.55
66 1 2 1 2 155 22.4 1 3 2 10.3 13 1.1
45 1 2 1 2 154 23.8 1 3 2 9.5 16 1.55
56 1 1 1 2 344 21.1 1 1 1 11.5 22 3.12
67 2 2 1 2 238 25.5 1 2 1 13.5 21 3.2
75 2 2 1 2 200 25 1 2 1 13.2 20.8 3.56
47 2 1 1 2 276 28 2 2 1 12.5 21 3.44
68 1 2 1 1 265 26.6 2 2 1 13.5 21 3.11
67 1 1 1 1 230 21.8 2 1 1 12.8 23 2.99
39 1 2 1 1 300 25.5 2 1 1 12 20 3.22
49 1 1 1 1 231 22.9 2 2 1 11.8 19 3.65
59 1 1 2 1 199 22.9 2 3 2 11.5 10 2.4
66 1 1 2 2 176 21.1 2 3 2 10.9 11 2.85
55 2 1 2 2 300 26.9 2 1 1 12.7 22 2.77
56 2 2 1 2 222 20.5 2 1 1 13.7 20 2.6
